Transcriptomics Technologies Market Size

Transcriptomics Technologies Market size was over USD 6.97 billion in 2024 and is poised to exceed USD 16 billion by 2037, growing at over 6.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of transcriptomics technologies is evaluated at USD 7.34 billion. It is anticipated that companies in the worldwide market would have abundant growth prospects due to the rising incidence of cancer. The American Cancer Society projects that in 2019, there will be 606,880 cancer-related deaths in the United States and 1,762,450 new instances of cancer identified.

In addition to these, the ongoing enhancement of the healthcare infrastructure and the growing investments in research & development are giving the market a significant boost in growth. The necessity for drug research and development is underscored by the global incidence of diseases including diabetes, hepatitis B, and cancer, which is also a major factor propelling the transcriptomics technologies market.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of transcriptomics technologies is evaluated at USD 7.34 billion.

The transcriptomics technologies market size was over USD 6.97 billion in 2024 and is poised to exceed USD 16 billion by 2037, growing at over 6.6% CAGR during the forecast period i.e., between 2025-2037. Rising incidence of cancer and expenditure on research & development will drive the market growth.

North America industry is anticipated to dominate majority revenue share of 33% by 2037, impelled by rise in technological advancements and the expansion of drug discovery practices in the region.

The major players in the market include Danaher Corporation, Agilent Technologies, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Pacific Bioscience of California, Inc., BioSkryb Genomics, Agilent Technologies Inc., Parse Biosciences

Transcriptomics Technologies Market Size